Cargando…

Niacin or Ezetimibe for Patients with, or at Risk of Coronary Heart Disease

Coronary heart disease treatment with HMG-CoA reductase inhibitors has been very successful. There is increasing interest in adding other lipid lowering therapy, primarily as additional therapy onto HMG-CoA reductase therapy. This paper will examine two of the more popular secondary agents, ezetimib...

Descripción completa

Detalles Bibliográficos
Autor principal: Guthrie, Robert
Formato: Texto
Lenguaje:English
Publicado: Libertas Academica 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2978935/
https://www.ncbi.nlm.nih.gov/pubmed/21079754
http://dx.doi.org/10.4137/CMC.S5970

Ejemplares similares